Tessellate BIO Emerges from Stealth - Replimune Group (NASDAQ:REPL), NewAmsterdam Pharma (NASDAQ:NAMS)

The company aims to become a global leader in precision oncology by redefining Synthetic Lethality to treat large, currently unserved patient populationsLead program targets Alternative Lengthening of Telomeres (ALT)

Related Keywords

Amsterdam ,Noord Holland ,Netherlands ,Portugal ,London ,City Of ,United Kingdom ,Australia ,Rogier Rooswinkel ,Chris Gardner ,Hilda Pickett ,Andree Blaukat ,Sue Charles ,Daniela Couto ,Eliot Forster ,Claus Azzalin ,Andrew Lightfoot ,Linkedin ,Head Of Oncology Research At Merck Kga ,Children Medical Research Institute ,Synthetic Lethality ,Alternative Lengthening ,Biogeneration Ventures ,While Synthetic Lethality ,Homology Recombination Deficiency ,Oncology Research ,Molecular Oncology Unit ,General Partner ,Independent Director ,Medical Research Institute ,Instituto De Medicina Molecular ,Stevenage Bioscience Catalyst ,Generation Ventures ,